Harvard University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
100
About the Report
About the Report
Summary
Harvard University (Harvard) is an educational and research university that offers undergraduate and post graduate programs. The university offers courses such as accounting and management, anthropology, epidemiology, mathematics, music, pathology, psychology, sociology, visual and environmental studies, women's studies in religion, physics. It provides courses such as pediatric dentistry; landscape, architecture, and urban planning; biological chemistry and molecular pharmacology; comparative literature and microbiology and molecular genetics. Harvard offers libraries, museums, laboratories and research centers to support scholarly work. The university collaborates with other universities and research institutions for its research activities. It operates through various schools and colleges. Harvard is headquartered in Cambridge, Massachusetts, the US.
Harvard University-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Harvard University, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Harvard University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Harvard University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Harvard University, Medical Devices Deals, 2012 to YTD 2018 12
Harvard University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Harvard University, Pharmaceuticals & Healthcare, Deal Details 17
Partnerships 17
Beam Therapeutics Enters into Licensing Agreement with Harvard University 17
Bristol-Myers Squibb Enters into Research Agreement with Harvard Stem Cell Institute 18
Frequency Therapeutics Enters into Agreement with Harvard University and US Army Institute of Surgical Research 19
Les Laboratoires Servier Enters into Agreement with Harvard University 20
Vir Biotechnology and Harvard University Enter into Research Agreement 21
Elysium Health Enters into Research Agreement with Harvard University 22
Thrive Bioscience and Harvard Stem Cell Institute Enter into Agreement 23
Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute 24
Kiromic Enters into Agreement with Harvard Medical School 25
ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School 26
Medgenics Enters into Agreement with Harvard University 27
Ipsen Enters into Research Agreement with Harvard University 28
AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 29
Imcare Biotech Enters into Partnership with Harvard Medical School 30
Astellas Pharma Enters into Research Agreement with Harvard Medical School 31
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 32
Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 33
Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 34
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 35
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 36
Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 37
Emory University And Children's Hospital of Philadelphia Enter Into Co-Development Agreement With Harvard University 38
UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 39
Pfizer Enters Into Co-Development Agreement With Harvard University 40
UCB Enters Into Co-Development Agreement With Harvard University 41
Evotec Enters Into Co-Development Agreement With Harvard University And BWH 42
Licensing Agreements 44
Elysium Health Enters into Licensing Agreement with Mayo Clinic and Harvard University 44
Symbiotix Biotherapies Enters into Licensing Agreement with Harvard University 45
Novartis Enters into Licensing Agreement with SEAS, Wyss Institute for Biologically Inspired Engineering, Dana-Farber Cancer Institute and University of Michigan 46
Mustang Bio Enters into Licensing Agreement with Harvard University 47
X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School 48
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 49
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 51
Nobilis Therapeutics Enters into Licensing Agreement with Harvard University 53
Merck Enters into Licensing Agreement with Harvard University 54
Mesoblast Enters into Licensing Agreement with Harvard Medical School 55
Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 56
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 57
Columbia Labs Enters into Licensing Agreement for IVR Technology 59
Macrolide Pharma Enters into Licensing Agreement with Harvard University Office of Technology Development 60
H&P Labs Enters into Licensing Agreement with Harvard University and Brigham and Women's Hospital 61
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 62
SciFluor Life Sciences Extends Licensing Agreement With Harvard University For PET Imaging 64
Semma Therapeutics Enters into Licensing Agreement with Harvard University 65
Allied-Bristol Life Sciences Enters into Licensing Agreement with Harvard University 66
Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 67
GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School 68
TissueNetix Enters Into Licensing Agreement With Harvard University For Muscular Thin Film Technology 69
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 70
Insero Health Enters Into Patent Licensing Agreement With Harvard University 72
Harvard University-Key Competitors 73
Harvard University-Key Employees 74
Harvard University-Locations And Subsidiaries 75
Head Office 75
Other Locations & Subsidiaries 75
Recent Developments 77
Legal and Regulatory 77
Sep 10, 2018: CRISPR Therapeutics, Intellia Therapeutics & Caribou Biosciences provide update on US federal circuit decision upholding the ruling by US patent and trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology 77
Government and Public Interest 78
Aug 29, 2018: New therapy spurs nerve fibers to regrow through scar tissue, transmit signals after spinal cord injury in rodents 78
Aug 20, 2018: Taking the brain apart to put it all together again 80
Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 82
Apr 04, 2018: Hearing loss study at USC, Harvard shows hope for millions 83
Mar 19, 2018: Metastatic Prostate Cancer Project Explores a New Approach to Genomics Research 84
Mar 12, 2018: Switch that could improve memory identified 86
Mar 05, 2018: Personal cancer vaccines get their own boost 87
Dec 27, 2017: Technical University of Munich: Double strike against tuberculosis 89
Dec 20, 2017: CRISPR therapy preserves hearing in progressive deafness model 90
Nov 16, 2017: Study shows codeine prescribed to children despite FDA warning against it 92
Feb 10, 2017: U.S. Scientists Receive Inaugural USD 87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner 93
Product News 94
Nov 29, 2017: Innovative Microscope Poised to Propel Optogenetics Studies 94
Aug 20, 2018: NCI-led research team develops predictor for immunotherapy response in melanoma 96
Jun 27, 2018: New approach may eliminate daily injections for diabetics 97
Other Significant Developments 98
Jun 13, 2018: Researchers can count on improved proteomics method 98
Jun 05, 2018: Organ-on-Chip: a Growing MedTech Market Opportunity for Sensera MEMs 99
Appendix 100
Methodology 100
About GlobalData 100
Contact Us 100
Disclaimer 100
List of Figure
List of Figures
Harvard University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Harvard University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Harvard University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Harvard University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Harvard University, Medical Devices Deals, 2012 to YTD 2018 12
List of Table
List of Tables
Harvard University, Pharmaceuticals & Healthcare, Key Facts 2
Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Harvard University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Harvard University, Deals By Therapy Area, 2012 to YTD 2018 10
Harvard University, Medical Devices Deals, 2012 to YTD 2018 12
Harvard University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Beam Therapeutics Enters into Licensing Agreement with Harvard University 17
Bristol-Myers Squibb Enters into Research Agreement with Harvard Stem Cell Institute 18
Frequency Therapeutics Enters into Agreement with Harvard University and US Army Institute of Surgical Research 19
Les Laboratoires Servier Enters into Agreement with Harvard University 20
Vir Biotechnology and Harvard University Enter into Research Agreement 21
Elysium Health Enters into Research Agreement with Harvard University 22
Thrive Bioscience and Harvard Stem Cell Institute Enter into Agreement 23
Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute 24
Kiromic Enters into Agreement with Harvard Medical School 25
ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School 26
Medgenics Enters into Agreement with Harvard University 27
Ipsen Enters into Research Agreement with Harvard University 28
AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 29
Imcare Biotech Enters into Partnership with Harvard Medical School 30
Astellas Pharma Enters into Research Agreement with Harvard Medical School 31
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 32
Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 33
Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 34
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 35
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 36
Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 37
Emory University And Children's Hospital of Philadelphia Enter Into Co-Development Agreement With Harvard University 38
UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 39
Pfizer Enters Into Co-Development Agreement With Harvard University 40
UCB Enters Into Co-Development Agreement With Harvard University 41
Evotec Enters Into Co-Development Agreement With Harvard University And BWH 42
Elysium Health Enters into Licensing Agreement with Mayo Clinic and Harvard University 44
Symbiotix Biotherapies Enters into Licensing Agreement with Harvard University 45
Novartis Enters into Licensing Agreement with SEAS, Wyss Institute for Biologically Inspired Engineering, Dana-Farber Cancer Institute and University of Michigan 46
Mustang Bio Enters into Licensing Agreement with Harvard University 47
X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School 48
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 49
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 51
Nobilis Therapeutics Enters into Licensing Agreement with Harvard University 53
Merck Enters into Licensing Agreement with Harvard University 54
Mesoblast Enters into Licensing Agreement with Harvard Medical School 55
Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 56
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 57
Columbia Labs Enters into Licensing Agreement for IVR Technology 59
Macrolide Pharma Enters into Licensing Agreement with Harvard University Office of Technology Development 60
H&P Labs Enters into Licensing Agreement with Harvard University and Brigham and Women's Hospital 61
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 62
SciFluor Life Sciences Extends Licensing Agreement With Harvard University For PET Imaging 64
Semma Therapeutics Enters into Licensing Agreement with Harvard University 65
Allied-Bristol Life Sciences Enters into Licensing Agreement with Harvard University 66
Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 67
GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School 68
TissueNetix Enters Into Licensing Agreement With Harvard University For Muscular Thin Film Technology 69
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 70
Insero Health Enters Into Patent Licensing Agreement With Harvard University 72
Harvard University, Key Competitors 73
Harvard University, Key Employees 74
Harvard University, Other Locations 75
Harvard University, Subsidiaries 75
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.